CEO and CFO Share Purchases
05/04/2023 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230405:nRSE3905Va&default-theme=true
RNS Number : 3905V Tissue Regenix Group PLC 05 April 2023
Tissue Regenix Group plc
('Tissue Regenix' or the 'Company')
CEO and CFO Share Purchases
( )
Tissue Regenix (AIM: TRX), the regenerative medical device company, announces
that on 4 April 2023, Daniel Lee, Chief Executive Officer, and David Cocke,
Chief Financial Officer each purchased 1,428,570 of the Company's ordinary
shares of 0.1p each ("Ordinary Shares").
Name Title Number of Ordinary Shares purchased Resulting beneficial interest in the Company's Ordinary Shares Percentage of Company's Total Voting Rights
Daniel Lee Chief Executive Officer 1,428,570 8,690,770 0.12%
David Cocke Chief Financial Officer 1,428,570 7,120,570 0.10%
For more information:
Tissue Regenix Group plc www.tissueregenix.com (http://www.tissueregenix.com)
David Cocke, Chief Financial Officer Via Walbrook PR
finnCap Ltd (Nominated Adviser and Broker)
Emily Watts/Geoff Nash/George Dollemore - Corporate Finance
Nigel Birks/Harriet Ward - ECM
Walbrook PR (Financial PR & IR) Tel: +44(0)20 7933 8780
Alice Woodings / Lianne Applegarth TissueRegenix@walbrookpr.com
About Tissue Regenix (www.tissueregenix.com)
Tissue Regenix is a leading medical device company in the field of
regenerative medicine. The Company's patented decellularisation technology
('dCELL®') removes DNA and other cellular material from animal and human soft
tissue, leaving an acellular tissue scaffold which is not rejected by the
patient's body and can then be used to repair diseased or damaged body
structures. Current applications address many critical clinical needs in
sports medicine, foot and ankle and wound care.
In August 2017, Tissue Regenix acquired CellRight Technologies®, a biotech
company that specialises in regenerative medicine and is dedicated to the
development of high quality, innovative tissue scaffolds, which can enhance
healing opportunities in defects created by trauma and disease. CellRight®'s
human tissue products may be used in spine, trauma, general orthopaedic,
dental and ophthalmological surgical procedures.
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Daniel Lee
2 Reason for the notification
a) Position/status Chief Executive Officer
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Tissue Regenix Group plc
b) LEI 213800PNOD5UHQUFJI36
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 0.1p each
Identification code GB00B5SGVL29
b) Nature of the transaction Purchase
c) Price(s) and volume(s)
Price(s) Volume(s)
0.5700p 500,000
0.5650p 928,570
d) Aggregated information
- Aggregated volume 1,428,570
- Price £8,096.42
e) Date of the transaction 4 April 2023
f) Place of the transaction London Stock Exchange, AIM Market
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name David Cocke
2 Reason for the notification
a) Position/status Chief Financial Officer
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name Tissue Regenix Group plc
b) LEI 213800PNOD5UHQUFJI36
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares of 0.1p each
Identification code GB00B5SGVL29
b) Nature of the transaction Purchase
c) Price(s) and volume(s)
Price(s) Volume(s)
0.5700p 500,000
0.5650p 928,570
d) Aggregated information
- Aggregated volume 1,428,570
- Price £8,096.42
e) Date of the transaction 4 April 2023
f) Place of the transaction London Stock Exchange, AIM Market
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHKZGGDRDKGFZM